Who are RPH-051's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Otezla, Crisaborole ointment, 2%, Crisaborole Vehicle, Apremilast (CC-10004), LAS41008, COV795.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rph-051.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

RPH-051 — Competitive Intelligence Brief

RPH-051 (RPH-051) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PDE4 inhibitor. Area: Immunology.

phase 3 PDE4 inhibitor PDE4 Immunology Small molecule Live · refreshed every 30 min

Target snapshot

RPH-051 (RPH-051) — R-Pharm. RPH-051 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
RPH-051 TARGET	RPH-051	R-Pharm	phase 3	PDE4 inhibitor	PDE4
Otezla	APREMILAST	Amgen	marketed	Phosphodiesterase 4 Inhibitor [EPC]	PDE4	2014-01-01
Crisaborole ointment, 2%	Crisaborole ointment, 2%	Pfizer	marketed	Phosphodiesterase 4 (PDE4) inhibitor	PDE4
Crisaborole Vehicle	Crisaborole Vehicle	Pfizer	marketed	Phosphodiesterase 4 (PDE4) inhibitor	PDE4
Apremilast (CC-10004)	Apremilast (CC-10004)	Virginia Clinical Research, Inc.	marketed	Phosphodiesterase 4 (PDE4) inhibitor	PDE4
LAS41008	LAS41008	Almirall, S.A.	phase 3	PDE4 inhibitor	PDE4
COV795	COV795	Mallinckrodt	phase 3	Phosphodiesterase 4 (PDE4) inhibitor	PDE4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PDE4 inhibitor class)

GlaxoSmithKline · 7 drugs in this class
Almirall, S.A. · 4 drugs in this class
Pfizer · 3 drugs in this class
Dr. Reddy's Laboratories Limited · 1 drug in this class
Galderma R&D · 1 drug in this class
Handok Inc. · 1 drug in this class
R-Pharm · 1 drug in this class
Advenchen Pharmaceuticals, LLC. · 1 drug in this class
Shaanxi Micot Pharmaceutical Technology Co., Ltd. · 1 drug in this class
Amgen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RPH-051 — Competitive Intelligence Brief. https://druglandscape.com/ci/rph-051. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab